In the face of stagnant healthcare budgets, and evergrowing demand for care, value-based pricing has real potential to bring value to pharma companies, payers, patients…
From our partner, KPGM: The rules of engagement in the global pharmaceutical industry are changing rapidly with disruption in this industry already well underway. Two…
To develop a scientific discovery into a life-changing drug or technology, it takes experts from various fields. We have collaborated with Labiotech.eu to paint a…
Lonza, a pharmaceutical company from Basel, has published pleasing half-year results, with positive momentum driven by its new Consumer Health division. Lonza has reported 8.2 per…
The physician and pharmacologist Nicole Onetto is a member of the Board of Directors at the Basilea Pharmaceutica AG. In the Interview that was featured…
Basel is among the European biotech hubs with the most exciting companies as named by labiotech.eu. The industry platform highlighted businesses including Actelion, CRISPR Therapeutics…
Xconomy National — Arch Venture Partners co-founder and managing director Bob Nelsen is widely regarded as one of the most astute and successful life science investors and…
The Swiss biotech industry continued to grow in 2017. Reaching record figures in sales and capital investments in companies, according to a new report. New…
Targeted protein degradation is really taking off. Besides Arvinas, C4 Therapeutics, and Kymera, Cedilla Therapeutics, founded by Thirdrock Ventures, has emerged with a $56 million…